Exelixis Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating XL092 in Combination with Atezolizumab in Patients with Advanced Solid…
Posted: October 29, 2020 at 8:59 pm
Oct. 26, 2020 12:00 UTC
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ: EXEL) today announced enrollment of the first patient into the dose-escalation cohort of the combination arm of the phase 1 trial (NCT03845166) evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of XL092 alone and in combination with atezolizumab (TECENTRIQ) in patients with advanced solid tumors. XL092 is an investigational, next-generation oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER and other kinases implicated in the growth and spread of cancer.
This exciting update follows promising preclinical findings presented at the ENA Symposium suggesting that XL092, like cabozantinib, promotes an immune-permissive environment that may result in synergies with immune checkpoint inhibitors; however, as seen in the ongoing phase 1 study, XL092 has a much shorter pharmacokinetic half-life that may help physicians in managing tolerability, said Gisela Schwab, M.D., President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis. Enrolling the first patient into the combination therapy part of this trial is an important step forward in the development of XL092 as we explore how it may improve outcomes for patients with difficult-to-treat cancers and build on the success of our cabozantinib oncology franchise.
Initiated in February 2019, the dose-escalation evaluation of the XL092 monotherapy arm of the phase 1 trial is ongoing. Once the recommended doses of both single-agent XL092 and XL092 in combination with atezolizumab are established, the trial will begin to enroll expansion cohorts for patients with clear cell and non-clear cell renal cell carcinoma, hormone-receptor positive breast cancer and metastatic castration-resistant prostate cancer.
More information about this trial is available at ClinicalTrials.gov.
About XL092
XL092 is a next-generation oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancers growth and spread. In designing XL092, Exelixis sought to build upon the experience and target profile of cabozantinib, the companys flagship medicine, while improving key characteristics, including clinical half-life. XL092 is the first internally discovered Exelixis compound to enter the clinic following the companys reinitiation of drug discovery activities.
About CABOMETYX (cabozantinib)
In the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced RCC and for the treatment of patients with HCC who have been previously treated with sorafenib. CABOMETYX tablets have also received regulatory approvals in the European Union, Japan and additional countries and regions worldwide. In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan. In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the United States.
Important Safety Information
Warnings and Precautions
Hemorrhage: Severe and fatal hemorrhages occurred with CABOMETYX. The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies. Discontinue CABOMETYX for Grade 3 or 4 hemorrhage. Do not administer CABOMETYX to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena.
Perforations and Fistulas: Gastrointestinal (GI) perforations, including fatal cases, occurred in 1% of CABOMETYX patients. Fistulas, including fatal cases, occurred in 1% of CABOMETYX patients. Monitor patients for signs and symptoms of perforations and fistulas, including abscess and sepsis. Discontinue CABOMETYX in patients who experience a Grade 4 fistula or a GI perforation.
Thrombotic Events: CABOMETYX increased the risk of thrombotic events. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events occurred in CABOMETYX patients. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic event requiring medical intervention.
Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension occurred in 36% (17% Grade 3 and <1% Grade 4) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management; when controlled, resume at a reduced dose. Discontinue CABOMETYX for severe hypertension that cannot be controlled with anti-hypertensive therapy or for hypertensive crisis.
Diarrhea: Diarrhea occurred in 63% of CABOMETYX patients. Grade 3 diarrhea occurred in 11% of CABOMETYX patients. Withhold CABOMETYX until improvement to Grade 1 and resume at a reduced dose for intolerable Grade 2 diarrhea, Grade 3 diarrhea that cannot be managed with standard antidiarrheal treatments, or Grade 4 diarrhea.
Palmar-Plantar Erythrodysesthesia (PPE): PPE occurred in 44% of CABOMETYX patients. Grade 3 PPE occurred in 13% of CABOMETYX patients. Withhold CABOMETYX until improvement to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE.
Proteinuria: Proteinuria occurred in 7% of CABOMETYX patients. Monitor urine protein regularly during CABOMETYX treatment. Discontinue CABOMETYX in patients who develop nephrotic syndrome.
Osteonecrosis of the Jaw (ONJ): ONJ occurred in <1% of CABOMETYX patients. ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain, or slow healing of the mouth or jaw after dental surgery. Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold CABOMETYX for development of ONJ until complete resolution.
Impaired Wound Healing: Wound complications occurred with CABOMETYX. Withhold CABOMETYX for at least 3 weeks prior to elective surgery. Do not administer CABOMETYX for at least 2 weeks after major surgery and until adequate wound healing is observed. The safety of resumption of CABOMETYX after resolution of wound healing complications has not been established.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS, a syndrome of subcortical vasogenic edema diagnosed by characteristic findings on MRI, can occur with CABOMETYX. Evaluate for RPLS in patients presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.
Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Verify the pregnancy status of females of reproductive potential prior to initiating CABOMETYX and advise them to use effective contraception during treatment and for 4 months after the last dose.
Adverse Reactions
The most commonly reported (25%) adverse reactions are: diarrhea, fatigue, decreased appetite, PPE, nausea, hypertension, and vomiting.
Drug Interactions
Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice.
Strong CYP3A4 Inducers: If coadministration with strong CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage. Avoid St. Johns wort.
USE IN SPECIFIC POPULATIONS
Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose.
Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. CABOMETYX is not recommended for use in patients with severe hepatic impairment.
Please see accompanying full Prescribing Information https://cabometyx.com/downloads/CABOMETYXUSPI.pdf.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), COTELLIC (cobimetinib) and MINNEBRO (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit http://www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis belief that the immune-permissive environment promoted by XL092 may result in synergies with immune checkpoint inhibitors and that XL092s shorter pharmacokinetic half-life may help physicians in managing tolerability; the potential for XL092 to improve outcomes for patients with difficult-to-treat cancers and build on the success of Exelixis cabozantinib oncology franchise; and Exelixis plans to reinvest in its business to maximize the potential of the companys pipeline, including through targeted business development activities and internal drug discovery. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis continuing compliance with applicable legal and regulatory requirements; the potential failure of XL092 or the combination of XL092 and atezolizumab to demonstrate safety and/or efficacy in NCT03845166 and in future trials; uncertainties inherent in the product development process; the continuing COVID-19 pandemic and its impact on Exelixis research and development operations, including Exelixis ability to initiate new clinical trials and clinical trial sites, enroll clinical trial patients, conduct trials per protocol, and conduct drug research and discovery operations and related activities; the costs of conducting clinical trials, including the ability or willingness of Exelixis collaboration partners to invest in the resources necessary to complete the trials; Exelixis dependence on third-party vendors for the development, manufacture and supply of XL092; Exelixis ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs discussed under the caption Risk Factors in Exelixis Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 6, 2020, and in Exelixis future filings with the SEC. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a Japanese trademark.
TECENTRIQ (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005160/en/
- Trans Women are Taking Hormones Without Medical Supervision in Uganda - VICE UK - January 14th, 2021
- Multitasking Meds Combat HIV, Along With Alzheimer's and Diabetes - HivPlusMag.com - January 14th, 2021
- Racism and Bias Make Infertility Treatment Even More Inaccessible to Couples of Color - Well+Good - January 14th, 2021
- Functional Connectivity in Certain Brain Regions May Be Associated with Hormone Therapy Outcomes in Transgender Patients - Psychiatry Advisor - January 12th, 2021
- The best prenatal vitamins for women and how to take them to boost your fertility - Insider - INSIDER - January 12th, 2021
- Why I'm Sharing Everything About My Experience As a Pregnant Dad - VICE - January 12th, 2021
- Forum Health, LLC adds Meridian Health Center to its growing community of Integrative and Functional Medicine practitioners - Yahoo Finance - January 9th, 2021
- Current Approaches and Unmet Needs in the Treatment of Metastatic Breast Cancer - AJMC.com Managed Markets Network - January 9th, 2021
- Forum Health, LLC adds Healing Arts Center to its growing community of Integrative and Functional Medicine practitioners - Iosco County News Herald - January 9th, 2021
- Nonprofit providing unusual form of therapy for those on front lines puppy cams - The Denver Channel - January 9th, 2021
- UPDATED: Eli Lilly's transpacific bosom buddy Terns bags late-round funding to drive NASH hopefuls through the clinic - Endpoints News - January 9th, 2021
- Experts treat insomnia, anxiety caused by COVID-19 - Spartan Newsroom - Spartan Newsroom - January 9th, 2021
- 5 Ways Gut Health Affects Your Sex Life and How Probiotics Can Help - Healthline - January 9th, 2021
- Is 90% of Serotonin Found in the Gut? - Snopes.com - January 9th, 2021
- Telemedicine Is Revolutionizing Abortion Health Carein Ways Likely To Persist Long Past COVID - Ms. Magazine - January 9th, 2021
- Next-Generation Cytotoxic Therapy Moves Forward in mCRPC - OncLive - January 9th, 2021
- Transgender Health Program at the University of Utah - SLUG Magazine - January 9th, 2021
- Premature Menopause Market 2021-28 healthcare leads to shooting revenues with Novo Nordisk A/S, Pfizer, Allergan, Eli Lily and Company, Emcure... - January 9th, 2021
- The Men's Health Partners and Greenville Men's Clinic Merger Changes the Way Men's Healthcare is done in South Carolina - PR Web - December 30th, 2020
- My fertility treatment failed three times in 2020 and I discovered how to live with uncertainty - The Guardian - December 30th, 2020
- The 11 Healthiest Lunches to Have, According to Dietitians | Eat This Not That - Eat This, Not That - December 30th, 2020
- The Most Dangerous Soda Habits You Need to Kick, Say Doctors - Eat This, Not That - December 30th, 2020
- Type 2 diabetes: Blurred vision and floaters in the eyes are signs of high blood sugar - Express - December 30th, 2020
- 7 New Acne-Treating Ingredients Alternative Acne Treatments - Allure Magazine - December 30th, 2020
- Winter got you down? It could be Seasonal Affective Disorder - PostBulletin.com - December 30th, 2020
- Thyroid Stimulating Hormone Test Kit Market In-Depth Analysis Of Competitive Landscape, Executive Summary, Development Factors 2026 | Innodx,... - December 30th, 2020
- Lasofoxifene Emerges as Understanding of ESR1 Mutations Expands in ER+/HER2- Breast Cancer - OncLive - December 30th, 2020
- Tips for mental health resilience in the time of COVID - Plattsburgh Press Republican - December 30th, 2020
- Do you have symptoms of low testosterone? - KTAR.com - December 17th, 2020
- Why COVID-19 Might Lead to Erectile Dysfunction in Some People, According to Doctors - Prevention.com - December 17th, 2020
- Las Colinas Cancer Center is Recognized as a Leader in Clinical Research and Personalized Cancer Care - Irving Weekly - December 17th, 2020
- How to strengthen your immune system this winter - USA TODAY - December 17th, 2020
- You Might Not Absorb as Much Vitamin D as You ThinkHere's How to Maximize the Process - msnNOW - December 17th, 2020
- Coping with social isolation | News | standard.net - Standard-Examiner - December 17th, 2020
- Breast cancer screening and COVID-19 | Feeling Fit - yoursun.com - December 17th, 2020
- A Time to Man-Up: Supporting the Menopausal Women in Your Life - The Good Men Project - December 17th, 2020
- Heres the Deal With Your Junk Food Cravings - Health Essentials from Cleveland Clinic - December 16th, 2020
- Puberty blockers and consent to treatment: an analysis of the High Court's ruling - Communitycare.co.uk - December 16th, 2020
- New Global Pooled Analysis Supports Clinical Utility of Circulating Tumor Cell Count for Early Monitoring of Metastatic Breast Cancer - PRNewswire - December 16th, 2020
- This One Thing Can Predict Your Risk of Disease, Says Science - Yahoo Lifestyle - December 16th, 2020
- Period Poops: Why They Happen and What You Can Do About Them - LIVESTRONG.COM - December 16th, 2020
- Dozens of bird and mammal species have been saved from extinction since 1993 - Massive Science - December 16th, 2020
- Uniklinik RWTH Aachen is the First Hospital to Implement Sphingotec's Innovative Biomarkers in Clinical Routine with the Aim of Making Intensive Care... - December 16th, 2020
- How to Reduce the Winter Blues With Plant-Based Food - LIVEKINDLY - December 16th, 2020
- What Is Gambling Addiction and Problem Gambling? - GamblingNews.com - December 16th, 2020
- Why I was right to blow the whistle on the Tavistock Clinic over puberty blockers - Telegraph.co.uk - December 9th, 2020
- The Role of Race, Ethnicity, and Cancer in the Time of COVID-19 - AJMC.com Managed Markets Network - December 9th, 2020
- Northfield school district employee terminated for unauthorized treatment of infant; Rice County law-enforcement breaks theft ring; Big Woods State... - December 9th, 2020
- How Keke Palmer found out the truth about her PCOS - Nicki Swift - December 9th, 2020
- Gynecological cancers and the global COVID-19 pandemic - DocWire News - December 9th, 2020
- Here's how much sleep your kids need to stay healthy - INFORUM - December 9th, 2020
- Here Are The Types Of Birth Control Available In Malaysia And How Much They Cost - SAYS - December 9th, 2020
- Why some people never gain weight | Health Gulf News - Gulf News - December 9th, 2020
- Hudson Hormone Replacement Therapy and Anti-Aging in ... - December 7th, 2020
- LoveJoy Home | LOVEJOY Hormone Clinic - December 7th, 2020
- UK court rules against clinic in puberty blocking drugs case - ABC News - December 7th, 2020
- Parathyroid Hormone Testing in Veterans with Kidney Stones and Hypercalcemia - DocWire News - December 7th, 2020
- Noise For Now Connects The Indie Scene To Support Women's Health Care - UPROXX - December 7th, 2020
- Medical history from the year you were born - Bryan-College Station Eagle - December 7th, 2020
- Dar Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis -... - December 7th, 2020
- Epidemiology Forecast on Acromegaly and Gigantism to 2029 - - GlobeNewswire - November 24th, 2020
- IVF: "I was absolutely heartbroken the first time it didn't work" - RTE.ie - November 24th, 2020
- Earlier menopause, fewer pregnancies linked to early onset of progressive MS - West Central Tribune - November 23rd, 2020
- Healthy Living: Are you sick and tired of feeling sick and tired? - Leinster Leader - November 23rd, 2020
- Jan Morris, Celebrated Writer of Place and History, Is Dead at 94 - The New York Times - November 23rd, 2020
- How to Know If the Abortion Pill Worked and What to Do Next - Healthline - November 23rd, 2020
- For one breast cancer survivor in Gaza Strip, a journey of hardship and hope - UNFPA News - November 23rd, 2020
- 7 Causes of Excessive Gas That Aren't Food - LIVESTRONG.COM - November 23rd, 2020
- Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech - November 19th, 2020
- Judge awards $10M to family in 'wrongful life' case - West Haven Observer - November 19th, 2020
- Screen time increases with pandemic adjustments - RiverTowns - November 19th, 2020
- Everything you need to know about the abortion pill, according to a gynecologist - Insider - INSIDER - November 19th, 2020
- Cure for cancer is research: Clinical trials pave the way at TMH - Tallahassee Democrat - November 19th, 2020
- For one breast cancer survivor in Gaza Strip, a journey of hardship and hope - occupied Palestinian territory - ReliefWeb - November 19th, 2020
- What Happens to A Physical Therapy Clinic during COVID-19? - outsmartmagazine.com - November 13th, 2020
- Benefits of Singing: 10 Ways Singing Boosts Your Health - Healthline - November 13th, 2020
- Abortion haven - Illinois Times - November 13th, 2020
- Emma Roberts reveals she froze her eggs after fertility struggle: Everything you need to know about the process - Yahoo India News - November 13th, 2020
- Al Roker reveals prostate cancer diagnosis: What to know about one of the most common types of cancer in men - Fox News - November 13th, 2020
- Mental Illness Appears To Be Yet Another COVID Side Effect - Kaiser Health News - November 11th, 2020